Genenta Science Spa Stock Price, News & Analysis

Genenta Science (Nasdaq: GNTA) released its financial results for the six months ended June 30, 2022, reporting a net loss of €2.1 million, a reduction from a €4.0 million loss in the same period last year. The company has no revenues but holds €34.7 million in cash, sufficient to fund operations through 2024. Significant progress was made in the Phase 1/2a trial of Temferon for glioblastoma, with a median overall survival of 17 months reported. The trial has escalated to a higher dosing cohort and aims to assess new conditioning regimens for enhanced efficacy.

Genenta Science (NASDAQ: GNTA), a clinical-stage immune-oncology company, is set to showcase its innovative therapies at upcoming scientific and investor conferences. Key events include the Roth Inaugural Healthcare Opportunities on October 6 in New York and the European Society of Gene & Cell Therapy Congress from October 11-14 in Edinburgh, UK. The Society for Immunotherapy of Cancer’s Annual Meeting will follow from November 8-12 in Boston, MA. These presentations will feature groundbreaking research on genetically-modified hematopoietic stem cells and autologous macrophage-based immunotherapy targeting solid tumors.

Genenta Science (NASDAQ: GNTA) will present at several major investor conferences in September and October 2022. CEO Pierluigi Paracchi and CMO Carlo Russo will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13. They will also participate in a panel at the Cantor Fitzgerald’s Cell and Genetic Medicines Conference on September 15, focusing on manufacturing essentials. Lastly, they will present at Chardan’s 6th Annual Genetic Medicines Conference on October 3. More details and the investor presentation can be found on their investor relations page.

Bowling Green Bull (BGB) is a new initiative launched to connect Italian companies and entrepreneurs seeking growth in the U.S. financial markets. Supported by the American Chamber of Commerce in Italy and Genenta Science (Nasdaq: GNTA), BGB aims to facilitate interactions between listed and aspiring listed companies, banks, and advisors. The inaugural event is scheduled for autumn 2022, focusing on providing insights and guidelines for Italian firms navigating U.S. market entry.

Genenta Science (NASDAQ: GNTA) announced its participation in several scientific congresses in May and June 2022, showcasing advancements in immuno-gene therapy for cancer. Presentations include:

• ASGCT Annual Meeting: May 19 - TEM-GBM study findings.
• Brain Tumor Meeting: May 19-20 - Patient case using Temferon™.
• ASCO Annual Meeting: June 5 - Tumor immune microenvironment research.
• EHA Virtual Congress: June 10 - Gene-modified cells' effects.

Genenta focuses on innovative therapies targeting solid tumors to enhance immune responses.

Genenta Science (NASDAQ: GNTA) has appointed Tim Obara as Vice President of Business Development. Obara, who previously held senior roles at organizations such as AstraZeneca and GSK, is expected to enhance Genenta's commercial and R&D opportunities, particularly for its Temferon™ treatment. This therapy, currently in a phase 1/2a trial for glioblastoma multiforme patients, employs innovative gene therapy strategies. CEO Pierluigi Paracchi expressed optimism about Obara's experience aiding in the company's growth in solid tumor markets.

Genenta Science (NASDAQ: GNTA) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2021, with the SEC on May 2, 2022. The report is available on the company's investor relations website and the SEC's website. Genenta is specializing in hematopoietic stem cell gene therapy, particularly its Temferon™ treatment for Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter. The company emphasizes that forward-looking statements in the report are subject to risks and uncertainties, including those related to ongoing clinical trials.

Genenta Science (NASDAQ: GNTA) has announced an escalation in its ongoing Phase 1/2a clinical trial of Temferon™ for glioblastoma multiforme patients with an unmethylated MGMT gene promoter. The trial has dosed its first patient in cohort 6 at 3.0 x 10⁶ cells per kilogram, a 50% increase from the previous maximum dose, after no dose-limiting toxicities were observed. The company aims to complete patient enrollment in cohorts 6 and 7 by mid-2023. CEO Pierluigi Paracchi noted the significance of this step in confirming Temferon's mechanism and therapeutic potential.

Genenta Science (NASDAQ: GNTA) announced preliminary findings from its Phase 1/2a study of Temferon™ for glioblastoma multiforme (uMGMT-GBM). The results show Temferon's potential to modulate the tumor microenvironment, with a positive safety profile. Fifteen patients received the treatment, showing successful engraftment and no drug-limiting toxicities. Preliminary signals of biological activity were observed, including gene-marked cells in tumors of patients who underwent surgery. The findings will be presented at the ASGCT meeting on May 19, 2022.